Preliminary results of the use of scalp microneedling in different types of alopecia.


Journal

Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 05 02 2019
accepted: 12 06 2019
pubmed: 30 6 2019
medline: 15 12 2020
entrez: 30 6 2019
Statut: ppublish

Résumé

Androgenetic alopecia (AGA) is the result of progressive patterned hair density reduction and sometimes can be associated with telogen effluvium (TE). The efficacy of conventional therapy is variable, and therefore, there is a need for adjuvant and newer modalities of treatment in order to give faster and better outcomes. Microneedling has been reported to be a promising, effective, and safe new technique in the treatment of AGA. The aim of this study was to prove that microneedling procedure should be offered to patients with AGA and TE along with the existing therapeutic modalities, in order to obtain faster hair regrowth and, therefore, a better patient compliance. We collected data of 36 females, 29 with AGA, and 7 with TE, and 14 males with AGA between January 2017 and December 2018 and then treated with 3 session of microneedling over a total period of 6 months. No serious adverse side effects were reported. All the patients reported a partial or complete reduction in hair loss, associated to the perception of improvement of hair density and thickening of the hair shaft diameter, results confirmed by clinical iconography and trichoscopy. Scalp areas typical affected by AGA, that is, the vertex in males and the frontal area in females, are the ones that showed the greater percentage of improvement. Moreover, microneedling can have a role also in TE, especially when cosmetic procedures do not give enough results, because it induces a rapid arresting of the hair loss.

Sections du résumé

BACKGROUND BACKGROUND
Androgenetic alopecia (AGA) is the result of progressive patterned hair density reduction and sometimes can be associated with telogen effluvium (TE). The efficacy of conventional therapy is variable, and therefore, there is a need for adjuvant and newer modalities of treatment in order to give faster and better outcomes. Microneedling has been reported to be a promising, effective, and safe new technique in the treatment of AGA.
OBJECTIVE OBJECTIVE
The aim of this study was to prove that microneedling procedure should be offered to patients with AGA and TE along with the existing therapeutic modalities, in order to obtain faster hair regrowth and, therefore, a better patient compliance.
PATIENTS AND METHODS METHODS
We collected data of 36 females, 29 with AGA, and 7 with TE, and 14 males with AGA between January 2017 and December 2018 and then treated with 3 session of microneedling over a total period of 6 months.
RESULTS RESULTS
No serious adverse side effects were reported. All the patients reported a partial or complete reduction in hair loss, associated to the perception of improvement of hair density and thickening of the hair shaft diameter, results confirmed by clinical iconography and trichoscopy.
CONCLUSIONS CONCLUSIONS
Scalp areas typical affected by AGA, that is, the vertex in males and the frontal area in females, are the ones that showed the greater percentage of improvement. Moreover, microneedling can have a role also in TE, especially when cosmetic procedures do not give enough results, because it induces a rapid arresting of the hair loss.

Identifiants

pubmed: 31254437
doi: 10.1111/jocd.13061
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-650

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Sinclair RD. Disorders of hair. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology. 8th ed. Vol. 4. UK: Blackwell Publishing Ltd; 2010:66.16-66.31.
Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15-24.
Atanaskova Mesinkovska N, Bergfeld WF. Hair: what is new in diagnosis and management. Female pattern hair loss update: diagnosis and treatment. Dermatol Clin. 2013;31:119-127.
Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
Arora S, Gupta PB. Automated microneedling device-a new tool in dermatologist’s kit-a review. J Pak Med Assoc. 2012;22:354e7.
Singh A, Yadav S. Yadav microneedling: advances and widening horizons Indian. Dermatol Online J. 2016;7(4):244-254.
Iriarte C, Awosika O, Rengifo-Pardo M, Ehrlich A. Review of applications of microneedling in dermatology. Clin Cosmet Investig Dermatol. 2017;10:289-298.
Vedamurthy M. Mesotherapy. Indian J Dermatol Venereol Leprol. 2007;73:60-62.
Escobar-Chávez JJ, Bonilla-Martínez D, Angélica M, et al. Microneedles: A valuable physical enhancer to increase transdermal drug delivery. J Clin Pharmacol. 2011;51:964-977.
Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A Comprehensive Review. Dermatol Surg 2017; 43: 321-339.
Jeong K, Lee YJ, Kim JE, Park YM, Kim BJ, Kang H. Repeated microneedle stimulation induce the enhanced expression of hair-growth-related genes. Int J Trichology. 2012;4:117.
Kim BJ, Lim YY, Kim HM, et al. Hair follicle regeneration in mice after wounding by microneedle roller. Int J Trichology. 2012;4:117.
Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6-11.
Fertig RM, Gamret AC, Cervantes J, Tosti A. Microneedling for the treatment of hair loss? JEADV. 2018;32:564-569.
Liebl H, Kloth LC. Skin cell proliferation stimulated by microneedles. J Am Coll Clin Wound Spec. 2012;4:2-6.
Jha AK, Udayan UK, Roy PK, Jha Amar AK, Chaudhary R. Platelet-rich plasma with microneedling in androgenetic alopecia along with dermoscopic pre- and post- treatment evaluation. J Cosmet Dermatol. 2018;17:313-318.

Auteurs

Michela Starace (M)

Department of Experimental, Diagnostic and Specialty Medicine-Division of Dermatology, University of Bologna, Bologna, Italy.

Aurora Alessandrini (A)

Department of Experimental, Diagnostic and Specialty Medicine-Division of Dermatology, University of Bologna, Bologna, Italy.

Nicolò Brandi (N)

Department of Experimental, Diagnostic and Specialty Medicine-Division of Dermatology, University of Bologna, Bologna, Italy.

Bianca Maria Piraccini (BM)

Department of Experimental, Diagnostic and Specialty Medicine-Division of Dermatology, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH